Lupin receives USFDA’s nod for Mycophenolic Acid Delayed-Release Tablets

19 Dec 2019 Evaluate

Lupin has received approval for its Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.  Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg (RLD: Myfortic) had an annual sales of approximately $174 million in the U.S. (IQVIA MAT Sept ember 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×